SCHEMBL20533689

SCHEMBL20533689

CCOC(=O)Cc1cn2cc(Br)ncc2n1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.43
ALDH1A1 P00352 7/20 0.43
KMT2A Q03164 6/20 0.41
MEN1 O00255 5/20 0.41
MAPT P10636 4/20 0.41
POLB P06746 3/20 0.41
ESR1 P03372 1/20 0.41
RECQL P46063 1/20 0.41
ESR2 Q92731 1/20 0.41
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
THRB P10828 1/20 0.38
RXFP1 Q9HBX9 1/20 0.37
MAPK1 P28482 2/20 0.36
HTT P42858 1/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4822612 0.80 KDM4E (0.47) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL20384719 0.78 KDM4E (0.58) KDM4EALDH1A1KMT2AMAPTPOLB
SCHEMBL15068790 0.78 KDM4E (0.49) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL7981086 0.77 KDM4E (0.44) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL16797787 0.77 KDM4E (0.44) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL19736704 0.77 AKT1 (0.51) KDM4EALDH1A1MAPTPOLBRECQL
SCHEMBL20985955 0.75 KDM4E (0.53) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL7982714 0.75 KDM4E (0.44) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL15230641 0.75 KDM4E (0.71) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL15068509 0.75 KDM4E (0.56) KDM4EALDH1A1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107690434-B Fused tricyclic imidazopyrazine derivatives as modulators of TNF activity UCB生物制药私人有限公司 2021-07-30 CN disclosed
EP-3303337-B1 FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SRL (BE) 2020-05-27 EP disclosed
US-10472362-B2 Fused tricyclic imidazo pyrazines as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2019-11-12 US disclosed
US-20180298006-A1 Fused Tricyclic Imidazo Pyrazines as Modulators of TNF Activity UCB S.A. (BE) 2018-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180298006-A1 Fused Tricyclic Imidazo Pyrazines as Modulators of TNF Activity TNF, TNFRSF1A, TNFRSF9 KDM4E 4765/4885ALDH1A1 1598/4885KMT2A 3801/4885
US-10472362-B2 Fused tricyclic imidazo pyrazines as modulators of TNF activity TNF, TNFRSF1A, TNFRSF9 KDM4E 4720/4885ALDH1A1 1283/4885KMT2A 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.